Thanks Dr T, that's a convincing explanation.
The problem is that even the largest Australian institutional super funds don't have biotech analysts, and neither do the fund managers to whom they outsource if they aren't managing in-house.
RAC - Charts & Price Action, page-332
-
- There are more pages in this discussion • 21,915 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.000(0.00%) |
Mkt cap ! $289.7M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.70 | $1.65 | $100.0K | 59.95K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 601 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 4823 | 3 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |